Health and Healthcare

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

117 Articles

Chris Lange | Sep 3, 2014 at 11:50 AM EDT

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm.

Jon C. Ogg | Jun 11, 2014 at 5:02 PM EDT

Orexigen Irony: No VIVUS Bounce

ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a…

Jon C. Ogg | Jan 3, 2014 at 8:30 AM EST

Biotech Stocks Under $10 With Huge Upside Potential for 2014

24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10…

Trey Thoelcke | Dec 19, 2013 at 8:30 AM EST

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.

Jon C. Ogg | Oct 3, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Jon OggWith the government shut down and with the debt ceiling debate breathing down everyone’s neck, investors have to be…

Jon C. Ogg | May 30, 2013 at 8:25 AM EDT

Jefferies Contrarian Stocks to Buy: Arena, Rackspace and More

ThinkstockIt is not unusual to see most research on Wall Street pretty much line up either for or against a…

Paul Ausick | May 3, 2013 at 4:04 PM EDT

Closing Bell for Thursday on Wall Street: Markets Rise to New Highs on Jobs Report

U.S. equity markets opened higher this morning following upward revisions from the Bureau of Labor Statistics on non-farm payrolls in…

Paul Ausick | May 3, 2013 at 8:30 AM EDT

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

ThinkstockDrug maker Arena Pharmaceuticals Inc. (NASDAQ: ARNA) has withdrawn its application for European regulatory approval of its weight-loss drug Belviq.…

Paul Ausick | Mar 4, 2013 at 4:02 PM EST

24/7 Wall St. Closing Bell — March 4, 2013: Markets Open Lower, Rise at End of Day (YHOO, NS, GPS, DF, MRK, ARNA, BYD, SSYS, RIG, YGE, CKP, CEP, FOE, SCSS, SSYS)

U.S. equity markets opened lower this morning following news out of China that government is about to tighten restrictions on…

Paul Ausick | Mar 1, 2013 at 4:03 PM EST

24/7 Wall St. Closing Bell — March 1, 2013: Markets Struggle to Small Gains (DB, V, DRI, BUD, ADSK, BODY, CTIC, CLNE, DECK, GPS, MCP, PANW, SD, BBY, ARNA, BYD, SSYS, RIG, GRPN, MTG, IEP)

U.S. equity markets opened lower this morning following a number of disappointing data releases in Europe and Asia. Eurozone PMI…

Jon C. Ogg | Feb 25, 2013 at 5:08 PM EST

VIVUS Obesity Drug Sales Only About 60% of Expectations

ThinkstockVIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings…

Jon C. Ogg | Feb 21, 2013 at 5:20 PM EST

Europe Denies Obesity Drug Approval

ThinkstockIf you are obese in Europe, you are not about to get a little pill to take to help you change.…

Jon C. Ogg | Feb 6, 2013 at 8:30 AM EST

Top Analyst Upgrades and Downgrades (ACI, ARNA, ADP, IRE, BOH, DELL, FHN, FSLR, FULT, GSS, HSY, INTU, ITRI, JCP, WFR, PNC, RF, SPWR, STP, TCB, USB, VIA, VVUS, WFC)

Jon OggThese are some of this Wednesday’s top analyst upgrades, downgrades and initiations seen from Wall S. research calls. We…

Jon C. Ogg | Feb 1, 2013 at 9:04 AM EST

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Paul Ausick | Jan 22, 2013 at 4:04 PM EST

24/7 Wall St. Closing Bell — January 22, 2013: Markets Shake Off Early Doldrums (TWC, SLB, DISH, ARMH, LNKD, DAL, FCX, JNJ, KSU, RF, VZ, AMD, CSX, GOOG, IBM, IGT, TXN, ABT, BHI, COH, GD, MCD, LCC, RIMM, DQ, LDK, ARNA)

U.S. equity markets opened about flat this morning following the holiday weekend in the U.S. Foreign markets were also more…

1 2 3 4 5 … 8

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Orexigen Irony: No VIVUS Bounce

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Jefferies Contrarian Stocks to Buy: Arena, Rackspace and More

Closing Bell for Thursday on Wall Street: Markets Rise to New Highs on Jobs Report

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

24/7 Wall St. Closing Bell — March 4, 2013: Markets Open Lower, Rise at End of Day (YHOO, NS, GPS, DF, MRK, ARNA, BYD, SSYS, RIG, YGE, CKP, CEP, FOE, SCSS, SSYS)

24/7 Wall St. Closing Bell — March 1, 2013: Markets Struggle to Small Gains (DB, V, DRI, BUD, ADSK, BODY, CTIC, CLNE, DECK, GPS, MCP, PANW, SD, BBY, ARNA, BYD, SSYS, RIG, GRPN, MTG, IEP)

VIVUS Obesity Drug Sales Only About 60% of Expectations

Europe Denies Obesity Drug Approval

Top Analyst Upgrades and Downgrades (ACI, ARNA, ADP, IRE, BOH, DELL, FHN, FSLR, FULT, GSS, HSY, INTU, ITRI, JCP, WFR, PNC, RF, SPWR, STP, TCB, USB, VIA, VVUS, WFC)

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

24/7 Wall St. Closing Bell — January 22, 2013: Markets Shake Off Early Doldrums (TWC, SLB, DISH, ARMH, LNKD, DAL, FCX, JNJ, KSU, RF, VZ, AMD, CSX, GOOG, IBM, IGT, TXN, ABT, BHI, COH, GD, MCD, LCC, RIMM, DQ, LDK, ARNA)

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Why Your Ex-Spouse Could Inherit Your $600,000 401(k) Even After Remarriage

Gold Went Flat in 2026. This Award-Winning Fund Still Milks 13% Income Out of It

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Why Your Ex-Spouse Could Inherit Your $600,000 401(k) Even After Remarriage

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Why Your Ex-Spouse Could Inherit Your $600,000 401(k) Even After Remarriage

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Orexigen Irony: No VIVUS Bounce

Biotech Stocks Under $10 With Huge Upside Potential for 2014

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

Top Analyst Upgrades and Downgrades: BlackBerry, Micron, SanDisk, VIVUS and More

Jefferies Contrarian Stocks to Buy: Arena, Rackspace and More

Closing Bell for Thursday on Wall Street: Markets Rise to New Highs on Jobs Report

Arena Withdraws Application for Weight-Loss Drug Approval in Europe

24/7 Wall St. Closing Bell — March 4, 2013: Markets Open Lower, Rise at End of Day (YHOO, NS, GPS, DF, MRK, ARNA, BYD, SSYS, RIG, YGE, CKP, CEP, FOE, SCSS, SSYS)

24/7 Wall St. Closing Bell — March 1, 2013: Markets Struggle to Small Gains (DB, V, DRI, BUD, ADSK, BODY, CTIC, CLNE, DECK, GPS, MCP, PANW, SD, BBY, ARNA, BYD, SSYS, RIG, GRPN, MTG, IEP)

VIVUS Obesity Drug Sales Only About 60% of Expectations

Europe Denies Obesity Drug Approval

Top Analyst Upgrades and Downgrades (ACI, ARNA, ADP, IRE, BOH, DELL, FHN, FSLR, FULT, GSS, HSY, INTU, ITRI, JCP, WFR, PNC, RF, SPWR, STP, TCB, USB, VIA, VVUS, WFC)

Positive Clinical Study Could Provide a Tailwind for Obesity Drugs (VVUS, ARNA, OREX)

24/7 Wall St. Closing Bell — January 22, 2013: Markets Shake Off Early Doldrums (TWC, SLB, DISH, ARMH, LNKD, DAL, FCX, JNJ, KSU, RF, VZ, AMD, CSX, GOOG, IBM, IGT, TXN, ABT, BHI, COH, GD, MCD, LCC, RIMM, DQ, LDK, ARNA)

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Why Your Ex-Spouse Could Inherit Your $600,000 401(k) Even After Remarriage

Gold Went Flat in 2026. This Award-Winning Fund Still Milks 13% Income Out of It

Featured Reads

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Why Your Ex-Spouse Could Inherit Your $600,000 401(k) Even After Remarriage